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Research
A streptococcus.1,2 With current treatments,
mortality still approaches 30% and survivors
may be left with chronic sequelae.3
Little is known about the epidemiology of
invasiv  GAS infection in Australia. A recent
study in northern Queensland reported an
annual incidence rate of 10.3 per 100 000 in
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Objective:  To estimate the incidence and severity of invasive group A streptococcal 
infection in Victoria, Australia.
Design:  Prospective active surveillance study.
Setting:  Public and private laboratories, hospitals and general practitioners throughout 
ria.
nts:  People in Victoria diagnosed with group A streptococcal disease notified to 
urveillance system between 1 March 2002 and 31 August 2004.
 outcome measure:  Confirmed invasive group A streptococcal disease.
lts:  We identified 333 confirmed cases: an average annualised incidence rate of 
5% CI, 2.3–3.2) per 100 000 population per year. Rates were highest in people aged 
65 years and older and those younger than 5 years. The case-fatality rate was 7.8%. 
Streptococcal toxic shock syndrome occurred in 48 patients (14.4%), with a case-fatality 
rate of 23%. Thirty cases of necrotising fasciitis were reported; five (17%) of these 
patients died. Type 1 (23%) was the most frequently identified emm sequence type in 
all age groups. All tested isolates were susceptible to penicillin and clindamycin. Two 
isolates (4%) were resistant to erythromycin.
Conclusion:  The incidence of invasive group A streptococcal disease in temperate 
Australia is greater than previously appreciated and warrants greater public health 
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attention, including its designation as a notifiable disease.ve
ge
coO r the past two decades, a resur-nce of invasive group A strepto-ccal (GAS) infection has been
observed in industrialised countries around
the world. This has been attributed to the
emergence of highly virulent strains of group
the non-Indigenous population and 82.5
per 100 000 in the Indigenous population,
with an overall mortality rate of 7%.4 These
estimates are substantially higher than those
reported from the Top End of the Northern
Territory (6.4 per 100 000 in the non-Indi-
genous population and 32.2 per 100 000 in
the Indigenous population).5 The only data
from non-tropical Australia came from a 12-
year review of admissions to the Royal Chil-
dren’s Hospital in Melbourne, which identi-
fied a clear increase in both disease
frequency and severity,6 consistent with
reports from the United States and Europe.
New approaches to the management of
invasive infections have emerged, including
the use of clindamycin in addition to peni-
cillin and the use of intravenous immune
globulin (IVIG) in the treatment of strepto-
coccal toxic shock syndrome (STSS).7-11
After decades of research, prophylactic can-
didate GAS vaccines are beginning to show
promise and may be available within the
next 10 years.12-17 To evaluate these inter-
ventions, comprehensive baseline data on
the burden of disease are critical. Therefore,
we established intensive, active surveillance
of invasive GAS infection in Victoria.
METHODS
Setting
The study was conducted in Victoria between 1
March 2002 and 31 August 2004. Victoria has a
population of about 4.3 million, a temperate
climate, and a demographic profile similar to
that of other industrialised countries. About
0.6% of the population identifies as Indigenous,
although this is thought to be an underestimate.
Surveillance system
Active surveillance of invasive GAS infection
was performed prospectively via a voluntary,
collaborative network of public and private
laboratories, hospitals and general practition-
ers from across Victoria. All laboratories in
Victoria that performed bacteriological testing
(n = 65 in 2001) were approached to partici-
pate. In addition to passive reporting, labora-
tories were contacted twice per month.
To capture cases not reported through
established channels, hospital discharge
datasets from all Victorian hospitals with an
intensive care unit or greater than 200-bed
capacity (n = 45 in 2001) were reviewed
every 3 months for ICD-10 (International
classification of diseases, 10th revision)
codes indicating GAS disease as a primary or
secondary discharge diagnosis.
Confirmed cases were defined as one of
the following:
• the isolation of group A streptococcus
from a normally sterile site (eg, blood, cer-
ebrospinal fluid, or other sterile fluid or
tissue);
• a clinical presentation of necrotising fas-
ciitis with evidence of GAS infection (eg,
culture of group A streptococcus or the
presence of gram-positive cocci from a tissue
specimen or wound swab or positive strep-
tococcal serology);
• a clinical presentation of pharyngeal
abscess (quinsy) requiring hospitalisation
and parenteral antibiotics with the isolation
of group A streptococcus from a throat
swab.
STSS was defined according to published
criteria (Box 1).18 Infections were classified
as nosocomially acquired if the collection
date of the first positive specimen was at
least 3 days after the hospital admission
date.
Demographic and clinical data were col-
lected from the treating physician and medi-
cal record review.
Laboratory methods
Available isolates underwent emm sequence
typing and penicillin susceptibility testing. A
subset of 50 randomly selected isolates (sam-
ple limited because of cost) underwent test-
ing to determine minimal inhibitory
concentrations (MIC) to penicillin, clindamy-
cin and erythromycin using the Etest methodMJA • Volume 186 Number 11 • 4 June 2007 565
RESEARCH(AB Biodisk, Solna, Sweden). Susceptibility
was assigned according to the interpretative
criteria for MIC recommended by the Clinical
and Laboratory Standards Institute.19
Data analysis
Denominators for the calculation of inci-
dence rates were the Victorian estimated
resident population (ERP) for 2002 and
2003 obtained from the Australian Bureau
of Statistics. Average annualised rates were
calculated by multiplying each year’s ERP by
the number of months of surveillance for
each year (eg, 2002 population by 10
months) and adding these totals. The total
number of cases over the 29 months was
then divided by the total person-months
and multiplied by 12. As data on onset of
illness were incomplete, onset was calcu-
lated as the earliest of hospital admission
date, specimen date or date of death. Data
were analysed using Stata, version 9 (Stata-
Corp, College Station, Tex, USA).
Ethics
The study was approved by the Victorian
Department of Human Services’ Ethics in
Human Research Committee and by more
than 70 individual health service ethics
committees.
RESULTS
Forty-five eligible hospitals and 63 laborato-
ries agreed to participate. Two laboratories
refused, but serviced hospitals for which
discharge data were available.
Epidemiological data
In the 30-month study period, 333 con-
firmed cases were identified. Three hundred
and fifteen (94.6%) were classified by the
isolation of group A streptococcus from a
sterile site, one was laboratory-confirmed
necrotising fasciitis with positive streptococ-
cal serology and group A streptococcus iso-
lated from a deep wound swab, and 17 were
pharyngeal abscesses. The average annual-
ised incidence rate was 2.7 (95% CI, 2.3–
3.2) per 100 000 population per year. Blood
cultures were positive in 240 patients
(72.1%) (annualised incidence of GAS
bacteraemia, 2.0 [95% CI, 1.6–2.4] per
100 000 population per year).
For the 302 patients whose age was
known, the mean age was 45.8 years (95%
CI, 42.6–49.0 years); 58 cases (19.2%)
occurred in children aged 0–15 years and
134 (44.4%) occurred in people aged 50
years and older. Incidence rates were highest
in people younger than 5 years and in those
65 years and older (Box 2). Fifty-three per
cent of cases occurred in males. Only two
cases were identified in Indigenous individ-
uals (average annual incidence rate, 2.9 per
100 000 population per year).
Among those for whom the information
was available, 97.8% (307/314) were hospi-
talised, the length of stay was  10 days for
48.7% (135/277), and 23.3% (67/288)
required admission to an intensive care unit.
Twenty-one (6.8%) of 307 hospitalised
1 Case definition of streptococcal 
toxic shock syndrome
A. Isolation of group A streptococcus
1. From a sterile site
2. From a non-sterile body site
B. Clinical signs of severity
1. Hypotension
2. Two or more of the following clinical or 
laboratory abnormalities:
a. Renal impairment
b. Coagulopathy
c. Liver abnormalities
d. Acute respiratory distress syndrome
e. Extensive tissue necrosis
f.  Erythematous rash
A definite case is defined as A1 + B(1 + 2)
A probable case is defined as A2 + B(1 + 2) ◆
2 Confirmed invasive group A streptococcal infection and average annualised incidence rate per 100 000 by age group 
(years), Victoria, 1 March 2002 to 31 August 2004
The inset shows data for the 0–4-years age group. ◆
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RESEARCHpatients were identified as having potentially
nosocomially acquired infections.
Soft tissue was the most common site of
infection (n=176) across all age groups (Box 3).
Among the patients for whom the informa-
tion was available, a pre-existing chronic
medical condition was reported in 66.2%
(182/275); heart and lung diseases predomi-
nated. Immunosuppression was reported in
18.7% of patients (52/278), and 23.8% (62/261)
reported use of non-steroidal anti-inflamma-
tory drugs within 14 days of symptom onset.
Preceding chickenpox was reported in 5%
(3/58) of paediatric patients. Other risk fac-
tors are listed in Box 4.
Severity and outcome
STSS was identified in 48 (14.4%) of the
333 patients, and necrotising fasciitis in 30
(10.9%) of 276 patients for whom the infor-
mation was available (Box 5). Twenty-five
deaths were known to have been due to GAS
disease (case-fatality rate, 7.8%). Six deaths
(24%) occurred in people younger than 65
years, including a 2-year-old child with a
history of sore throat who died of strepto-
coccal bacteraemia. All but three died within
10 days of admission to hospital. Of those
who died, only one person had received
IVIG and only eight had received clindamy-
cin in hospital. Four people who died were
immunocompromised; none was HIV posi-
tive. The focus of infection in 19 fatal cases
(76%) was soft tissue, of which five involved
necrotising fasciitis.
Where the information was available
(n = 285), 138 people (48.4%) required sur-
gery as a result of their GAS disease (includ-
ing debridement, washout, skin graft,
incision and drainage of abscesses, and
exploratory surgery) and of these, 13 (9.4%)
required amputation of a limb.
Laboratory data
Among the 255 available isolates on which
emm sequence typing was performed, 56
different types were identified; the top five
are presented in Box 6. Type 1 was the most
common in all age groups, and accounted for
42% of isolates from those who died, and
47% of STSS and 70% of necrotising fasciitis
cases. Sixty-two per cent of the isolates came
from emm types included in a 26-valent
serotype-specific GAS vaccine currently in
clinical trials.17 Emm types were available on
15 of the 21 nosocomial infections: three
were type 1, two were type 12, two were
type 28, and eight were individual types. No
epidemiological links were apparent.
All of the 50 isolates tested were suscepti-
ble to penicillin (all MICs < 0.024 μg/mL)
and clindamycin (all MICs < 0.20 μg/mL).
Two isolates (4%) were resistant to erythro-
mycin (MICs, 16 and 24 μg/mL; all other
MICs < 0.20 μg/mL).
DISCUSSION
Our study provides the first population-
based data on the epidemiology of invasive
GAS infection in non-tropical Australia. We
3 Specified diagnosis* by age group in people with confirmed invasive group A 
streptococcal infection, Victoria, 1 March 2002 to 31 August 2004
Age group (years)
Diagnosis
0–14 
(N = 58)
15–49 
(N = 110)
 50 
(N = 134)
Unknown 
(N = 31) Total† (%)
Soft tissue infection 20 56 86 14 176/266 (66.2%)
Cellulitis 11 47 74 14 146/182 (80.2%)
Necrotising fasciitis 0 14 14 2 30/276 (10.9%)
Septic arthritis 13 11 19 1 44/280 (15.7%)
Bacteraemia only 8 8 15 10 41/333 (12.3%)
Lower respiratory tract 13 16 12 2 43/279 (15.4%)
Pneumonia 8 14 12 2 36
Empyema 5 2 0 0 7
Upper respiratory tract 9 20 5 2 36/333 (10.8%)
Quinsy 3 12 0 2 17
Pharyngitis 2 2 0 0 4
Sinusitis 1 2 1 0 4
Other 3 4 4 0 11
Surgical site infection 2 9 12  2 25/277 (9.0%)
Osteomyelitis 5 3 2 0 10/270 (3.7%)
Other site 1 8 1 0 10/134 (7.5%)
Peritonitis 2 2 1 2 7/280 (2.5%)
Peripartum 0 6 0 0 6/286 (2.1%)
* More than one diagnosis may be specified per patient. † Denominator denotes number of patients for 
whom the information was available. ◆
4 Frequency of known risk factors 
for confirmed invasive group A 
streptococcal infection, Victoria, 
1 March 2002 to 31 August 2004
Risk factor n/N* %
Chronic medical condition 182/275 66.1%
Heart disease 66/283 23.3%
Lung disease 43/280 15.4%
Diabetes 31/281 11.0%
Liver disease (other than 
cirrhosis)
21/282 7.4%
Renal disease 15/279 5.4%
Haematological disorder 6/279 2.2%
Other† 137/283 48.4%
Cigarette smoking
Current 52/268 19.4%
Past 96/257 37.4%
Prior use of non-steroidal 
anti-inflammatory agents
62/261 23.4%
Immunosuppression‡ 52/278 18.7%
Includes 3 patients with HIV 3/280 1.1%
Any history of alcohol 
misuse
30/257 11.7%
Current 23/269 8.6%
Past 29/264 11.0%
Any history of IV drug use 26/270 9.4%
Current 23/278 8.3%
Past 23/277 8.3%
Recent history of 
chickenpox (all cases)
4/275 1.8%
Age < 15 years 3/58 5.0%
* Denominator represents patients for whom the 
information was available. Patients may have had 
more than one condition. † Includes endocrine 
disorders, autoimmune disorders, cerebrovascular 
disorders, mental illnesses, gastrointestinal 
disorders, glaucoma, metabolic disorders. 
‡ Includes systemic lupus erythematosus, HIV, 
hepatic cirrhosis, splenectomy, transplant, 
malignancy, sickle cell anaemia. ◆MJA • Volume 186 Number 11 • 4 June 2007 567
RESEARCHidentified an incidence rate of 2.7 per
100 000 population per year and a case-
fatality rate ranging from 7.8% for any dis-
ease to 23% for STSS. This disease predomi-
nantly affected the elderly and young
children. The most common focus of infec-
tion across all age groups was soft tissue,
which also accounted for an increasing pro-
portion of cases as age increased.
The incidence of disease, case-fatality
rate, predominance of cases in the elderly
and people with underlying medical condi-
tions, foci of infection and frequency of emm
type 1 among invasive isolates are consistent
with epidemiological data from other indus-
trialised countries.20-23 The incidence of
invasive GAS infection in non-Indigenous
people in tropical northern Australia is two
to four times greater than in Victoria.4,5 It is
not clear if these differences are attributable
to factors related to host susceptibility (eg,
increased prevalence of chronic conditions
and alcohol use), differences in environmen-
tal exposures, or differences in the virulence
of prevalent GAS strains. The differences in
emm type distribution between northern
Australia and Victoria reflect their divergent
epidemiologies. Cases in the north are
largely due to underlying skin infections,5
and the extreme diversity in emm types in
invasive GAS disease reflects the same diver-
sity in skin strains.5,24 The limited emm type
distribution in Victoria parallels that seen in
other industrialised countries.
The proportion of infections that were
nosocomially acquired is of concern. Inva-
sive GAS infection in health care settings can
be highly transmissible25 and is associated
with an increased risk of a fatal out-
come;26,27 institutional outbreaks are not
uncommon.28 In the US, it is recommended
that one nosocomial postpartum or postsur-
gical invasive GAS infection should initiate
enhanced surveillance and two or more
should prompt an epidemiological investi-
gation that includes carriage studies of
health care workers.29 Our data suggest
these recommendations are prudent and
should be considered in Australia.
We found a low proportion of varicella-
associated childhood cases compared with
between 15% and 27% of paediatric cases
reported elsewhere.30-32 The reasons for this
are unclear. Hospitalisation for childhood
varicella in Victoria occurs relatively late in
the illness,33 suggesting that the low rate of
varicella-associated invasive GAS infections
is not due to different behaviour in seeking
health care. However, at the time of this
study there was considerable public concern
surrounding invasive meningococcal disease
in Australia; it is possible that this may have
led parents of children with fever and rash to
present early to primary care practitioners.
Under-reporting is usually the most com-
mon problem with the use of surveillance
systems for providing burden of disease
data. Our system of reviewing hospital data
and regular contact with diagnostic labora-
tories suggests we are not likely to have
missed many confirmed cases. We included
in our case definition 18 cases that were not
confirmed by the isolation of group A strep-
tococcus from a sterile site. One of these was
a patient with necrotising fasciitis who had
both positive streptococcal serology and
group A streptococcus isolated from a deep
wound swab, and developed STSS. The
other 17 had pharyngeal abscesses (quinsy),
which are accepted invasive infections for
which the most common single pathogenic
species is group A streptococcus;34 all these
patients had positive throat swabs. Both
conditions require management as intensive
as for group A streptococcus confirmed by
sterile site isolates, and their exclusion
would underestimate disease burden.
The incidence of invasive GAS disease in
Victoria is similar to that of invasive menin-
gococcal disease before the introduction of
meningococcal C vaccine.35 Invasive menin-
gococcal disease has been legally notifiable
in all parts of Australia since 1991, with
comprehensive treatment and management
guidelines developed at a national level.35
Given the similarities, there is a case for
making invasive GAS infection notifiable in
Australia. This would be strengthened if an
increased risk of disease could be demon-
strated in close contacts of cases; we are
analysing our data to determine if this is the
case in Victoria. The frequency of nosoco-
mial infections provides impetus for the
development of guidelines to manage GAS
disease in institutions. The lack of use of
IVIG or clindamycin in fatal cases, despite
recommendations that they be used in
patients with severe invasive GAS infec-
tions,36-38 suggests a need for standard treat-
ment guidelines and education of health
professionals. A review of the approved indi-
cations for IVIG in Victoria is required, as
these do not currently include severe GAS
disease, potentially delaying the release of
the product for immediate use. The ongoing
development of vaccines, concerns about
antibiotic resistance and a growing body of
evidence that suggests disease is becoming
more severe in recent decades necessitate
ongoing population-based surveillance sys-
tems to monitor these trends and to inform
both clinical management and public health
policy.
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